(1) Medical Center Clinical Institute for Reproductive Medicine, Pleven, Bulgaria
(2) Department of Dermatology and Venereology, UMHAT “Dr. Georgi Stranski”, Medical University, Pleven, Bulgaria
ABSTRACT — OBJECTIVE: Human papillomavirus (HPV) persistent infections of genital tract are strongly related to the development of genital warts and cellular transformation. These infections lead to different type of anogenital cancers, including cervical, vulvar and vaginal.
Current therapeutic treatments of genital warts include surgical removal, physician-applied and patient-applied treatments. Most of these treatments aim to remove the wart, with low effect on virus infectivity. Therefore, recurrence rate represents a significant issue that has not been yet addressed. Moreover, adverse events and patient discomfort hamper the potential of these treatments. The aim of our study was to present a protocol proposal for the treatment of primary and recurrent genital warts based on Coriolus-MRL and polyhexamethylene biguanide application (PHMB).
PATIENTS AND METHODS: 42 Patients with primary (15 patients) and recurrent (27 patients) genital warts were treated with the immunostimulator Coriolus-MRL and PHMB solution. Coriolus-MRL (Mycology Research Laboratories Ltd, Luton, Bedfordshire, United Kingdom) was administered as 2 tablets, 3 times per day, for six months while PHMB-gynaecological solution, a mono-dose gynaecological liquid-gel, was prepared and self-administered by patients before bedtime, every four days for twenty days and, afterward, every twenty days for the following six months. The control group was treated only with Coriolus-MRL, 2 tablets, 3 times per day, for six months. All patients with recurrent genital warts were previously treated with podophyllin local therapy.
CONCLUSIONS: These results have demonstrated that combined therapy with Coriolus-MRL and PHMB solution provide positive outcomes in cases of primary or recurrent genital warts.
The Coriolus versicolor used in this preclinical study was supplied by Mycology Research Laboratories Ltd.
Link to article:
https://www.ijmdat.com/article/220
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Full Article
Clinical articles
-
Impact of Gastrointestinal Tract on Mushroom Biomass: Deciphering Their Potential on Gut Microbiota Modulation.
Helena Araújo-Rodrigues, Ana Sofia Salsinha, João Bettencourt Relvas, Freni K. Tavaria, Manuela E. Pintado Presented at the the 10th International Human Microbiome Consortium (IHMC) Congress held on June 22-25, 2024 in Rome Italy. -
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential.
Rosanna Di Paola, Rosalba Siracusa, Roberta Fusco, Marialaura Ontario, Gaetano Cammilleri, Licia Pantano, Maria Scuto, Mario Tomasello, Sestina Spanò, Angela Trovato Salinaro, Ali S. Abdelhameed, Vincenzo Ferrantelli, Antonio Arcidiacono, Tilman Fritsch, Gabriella Lupo, Anna Signorile, Luigi Maiolino, Salvatore Cuzzocrea, and Vittorio Calabrese.
Curr Neuropharmacol 2023 Dec 8. PMID: 38073105
-
Mushrooms as Functional Foods for Ménière’s Disease.
Victoria Bell and Tito Horácio Fernandes.
Appl. Sci. 2023, 13, 12348. -
Antioxidants, Hormetic Nutrition, and Autism.
Modafferi Sergio, Lupo Gabriella, Tomasello Mario, Rampulla Francesco, Ontario Marialaura,
Scuto Maria, Trovato Salinaro Angela, Arcidiacono Antonio, Anfuso Carmelina Daniela,
Legmouz Maria, Azzaoui Fatima-Zahra, Palmeri Agostino, Spano’ Sestina, Biamonte Francesca,
Cammilleri Gaetano, Fritsch Tilman, Sidenkova Alena, Calabrese Edward, Wenzel Uwe and Calabrese Vittorio. Curr Neuropharmacol. 2023 Aug 17.